## Massimo Raffaele Mannarino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9428708/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	The association between neutrophil to lymphocyte ratio and endothelial dysfunction in people living with HIV on stable antiretroviral therapy. Expert Review of Anti-Infective Therapy, 2022, 20, 113-120.	4.4	3
2	The detrimental impact of elevated Ferritin to Iron ratio on in-hospital prognosis of patients with COVID-19. Expert Review of Molecular Diagnostics, 2022, 22, 469-478.	3.1	7
3	Thyroid-Stimulating Hormone Predicts Total Cholesterol and Low-Density Lipoprotein Cholesterol Reduction during the Acute Phase of COVID-19. Journal of Clinical Medicine, 2022, 11, 3347.	2.4	4
4	The HACOR Score Predicts Worse in-Hospital Prognosis in Patients Hospitalized with COVID-19. Journal of Clinical Medicine, 2022, 11, 3509.	2.4	3
5	Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 327-336.	2.2	2
6	The Association between HDL-C and Subclinical Atherosclerosis Depends on CETP Plasma Concentration: Insights from the IMPROVE Study. Biomedicines, 2021, 9, 286.	3.2	7
7	Severe adverse drug reaction in <scp>SARSâ€CoV</scp> â€2 infection: <scp>AGEP</scp> induced by ceftriaxone and confirmed by patch test. Contact Dermatitis, 2021, 85, 366-368.	1.4	8
8	Association Between Uric Acid, Carotid Intimaâ€Media Thickness, and Cardiovascular Events: Prospective Results From the IMPROVE Study. Journal of the American Heart Association, 2021, 10, e020419.	3.7	22
9	A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Progress in Lipid Research, 2021, 84, 101127.	11.6	24
10	Prevalence of vitamin D deficiency and its prognostic impact on patients hospitalized with COVID-19. Nutrition, 2021, 91-92, 111408.	2.4	16
11	Low Brachial Artery Flow-Mediated Dilation Predicts Worse Prognosis in Hospitalized Patients with COVID-19. Journal of Clinical Medicine, 2021, 10, 5456.	2.4	16
12	Neutrophil to lymphocyte ratio is not related to carotid atherosclerosis progression and cardiovascular events in the primary prevention of cardiovascular disease: Results from the IMPROVE study. BioFactors, 2021, , .	5.4	9
13	Evaluation of Oxidative Stress Status in Familial Hypercholesterolemia. Journal of Clinical Medicine, 2021, 10, 5867.	2.4	15
14	Editorial: †Tea consumption and the risk of atherosclerotic cardiovascular disease and all-cause mortality: The China-PAR project'. European Journal of Preventive Cardiology, 2020, 27, 1953-1955.	1.8	1
15	Particulate matter pollution and the COVID-19 outbreak: results from Italian regions and provinces. Archives of Medical Science, 2020, 16, 985-992.	0.9	64
16	Time-related changes in sex distribution of COVID-19 incidence proportion in Italy. Heliyon, 2020, 6, e05304.	3.2	7
17	Commentary to "The Possible Role of Nutraceuticals in the Prevention of Cardiovascular Disease― High Blood Pressure and Cardiovascular Prevention, 2019, 26, 259-261.	2.2	1
18	Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study. Open Forum Infectious Diseases, 2019, 6, ofz112.	0.9	35

#	Article	IF	CITATIONS
19	Editorial commentary: Atherosclerosis and immunity: A perspective. Trends in Cardiovascular Medicine, 2019, 29, 372-373.	4.9	2
20	NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial. Atherosclerosis, 2019, 280, 51-57.	0.8	20
21	Elevated serum uric acid levels are associated with endothelial dysfunction in HIV patients receiving highly-active antiretroviral therapy. Atherosclerosis, 2018, 272, 101-107.	0.8	11
22	Autologous Cell Therapy for Vascular Regeneration: The Role of Proangiogenic Cells. Current Medicinal Chemistry, 2018, 25, 4518-4534.	2.4	12
23	Cholesterol-Lowering Nutraceuticals Affecting Vascular Function and Cardiovascular Disease Risk. Current Cardiology Reports, 2018, 20, 53.	2.9	31
24	PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?. Journal of Clinical Lipidology, 2018, 12, 1123-1132.	1.5	39
25	PCSK9 at the crossroad of cholesterol metabolism and immune function during infections. Journal of Cellular Physiology, 2017, 232, 2330-2338.	4.1	61
26	Lipoprotein(a) and inflammation: A dangerous duet leading to endothelial loss of integrity. Pharmacological Research, 2017, 119, 178-187.	7.1	59
27	Uric acid and bone mineral density in postmenopausal osteoporotic women: the link lies within the fat. Osteoporosis International, 2017, 28, 973-981.	3.1	19
28	Joint position statement on "Nutraceuticals for the treatment of hypercholesterolemia―of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 2-17.	2.6	81
29	Effects of a nutraceutical combination on lipids, inflammation and endothelial integrity in patients with subclinical inflammation: a randomized clinical trial. Scientific Reports, 2016, 6, 23587.	3.3	29
30	Urinary albumin-to-creatinine ratio is associated with endothelial dysfunction in HIV-infected patients receiving antiretroviral therapy. Scientific Reports, 2016, 6, 28741.	3.3	13
31	Non-alcoholic fatty liver disease fibrosis score and preclinical vascular damage in morbidly obese patients. Digestive and Liver Disease, 2016, 48, 904-908.	0.9	7
32	The effects of a nutraceutical combination on plasma lipids and glucose: A systematic review and meta -analysis of randomized controlled trials. Pharmacological Research, 2016, 110, 76-88.	7.1	94
33	Reduced survival in patients with early-stage non-small-cell lung cancer is associated with high pleural endothelial progenitor cell levels. European Journal of Cardio-thoracic Surgery, 2016, 50, 1053-1059.	1.4	3
34	An unusual emphysema. European Journal of Internal Medicine, 2015, 26, e45-e46.	2.2	2
35	Systemic inflammation and imbalance between endothelial injury and repair in patients with psoriasis are associated with preclinical atherosclerosis. European Journal of Preventive Cardiology, 2015, 22, 1027-1035.	1.8	40
36	Dyslipidemias and chronic kidney disease: a focus on pathogenesis and treatment. Clinical Lipidology, 2014, 9, 673-681.	0.4	3

#	Article	IF	CITATIONS
37	Nutraceuticals for the treatment of hypercholesterolemia. European Journal of Internal Medicine, 2014, 25, 592-599.	2.2	74
38	On-treatment C-reactive protein and HDL cholesterol levels in patients at intermediate cardiovascular risk: Impact on carotid intima-media thickness. Life Sciences, 2013, 93, 338-343.	4.3	7
39	Nutraceutical combination (red yeast rice, berberine and policosanols) improves aortic stiffness in low-moderate risk hypercholesterolemic patients. PharmaNutrition, 2013, 1, 73-77.	1.7	18
40	Baseline and post-surgery endothelial progenitor cell levels in patients with early-stage non-small-cell lung carcinoma: impact on cancer recurrence and survivalâ€. European Journal of Cardio-thoracic Surgery, 2013, 44, e245-e252.	1.4	11
41	Insulin Resistance and not BMI is the Major Determinant of Early Vascular Impairment in Patients with Morbid Obesity. Journal of Atherosclerosis and Thrombosis, 2013, 20, 924-933.	2.0	17
42	Non-cholesterol sterols in different forms of primary hyperlipemias. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 231-236.	2.6	22
43	Obstructive sleep apnea syndrome. European Journal of Internal Medicine, 2012, 23, 586-593.	2.2	244
44	Visceral fat positively correlates with cholesterol synthesis in dyslipidaemic patients. European Journal of Clinical Investigation, 2012, 42, 164-170.	3.4	22
45	Imbalance between endothelial injury and repair in patients with polymyalgia rheumatica: improvement with corticosteroid treatment. Journal of Internal Medicine, 2012, 272, 177-184.	6.0	25
46	Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic. European Journal of Internal Medicine, 2011, 22, 412-417.	2.2	15
47	Circulating immature osteoprogenitor cells and arterial stiffening in postmenopausal osteoporosis. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 636-642.	2.6	24
48	High weight or body mass index increase the risk of vertebral fractures in postmenopausal osteoporotic women. Journal of Bone and Mineral Metabolism, 2010, 28, 88-93.	2.7	98
49	Aortic stiffness and pulse wave reflection in young subjects with migraine. Neurology, 2010, 75, 960-966.	1.1	53
50	Determinants of the Ambulatory Arterial Stiffness Index Regression Line. Hypertension, 2009, 53, e33; author reply e34.	2.7	6
51	Influence of Short-term Rosuvastatin Therapy on Endothelial Progenitor Cells and Endothelial Function. Journal of Cardiovascular Pharmacology and Therapeutics, 2009, 14, 14-21.	2.0	58
52	Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk. Atherosclerosis, 2008, 197, 757-767.	0.8	76
53	Aortic Stiffness in Untreated Adult Patients With Human Immunodeficiency Virus Infection. Hypertension, 2008, 52, 308-313.	2.7	91
54	Review: Hypercholesterolemia-associated endothelial progenitor cell dysfunction. Therapeutic Advances in Cardiovascular Disease, 2008, 2, 329-339.	2.1	39

#	Article	IF	CITATIONS
55	Ambulatory Arterial Stiffness Index Is Not a Specific Marker of Reduced Arterial Compliance. Hypertension, 2007, 49, 986-991.	2.7	133
56	Age-Specific Relationship of Aortic Pulse Wave Velocity With Left Ventricular Geometry and Function in Hypertension. Hypertension, 2007, 49, 317-321.	2.7	113
57	Response to Dipping Deeper Into the Ambulatory Arterial Stiffness Index. Hypertension, 2007, 50, .	2.7	1
58	Reduced number of circulating endothelial progenitors and HOXA9 expression in CD34+ cells of hypertensive patients. Journal of Hypertension, 2007, 25, 2093-2099.	0.5	86
59	Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 436-441.	2.6	56
60	Prognostic Value of Elevated White Blood Cell Count in Hypertension. American Journal of Hypertension, 2007, 20, 364-369.	2.0	31
61	Metabolic syndrome and preclinical atherosclerosis: focus on femoral arteries. Metabolism: Clinical and Experimental, 2007, 56, 541-546.	3.4	20
62	Increased Ratio of CD31 <sup>+</sup> /CD42 <sup>â^'</sup> Microparticles to Endothelial Progenitors as a Novel Marker of Atherosclerosis in Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2530-2535.	2.4	128
63	Relation Between Renal Function Within the Normal Range and Central and Peripheral Arterial Stiffness in Hypertension. Hypertension, 2006, 48, 616-621.	2.7	88
64	Different Impact of the Metabolic Syndrome on Left Ventricular Structure and Function in Hypertensive Men and Women. Hypertension, 2006, 47, 881-886.	2.7	106
65	Treating Hypertensive Non-Dippers: Additional Benefit from Nocturnal Blood Pressure Reduction?. Cardiovascular Drugs and Therapy, 2005, 19, 169-171.	2.6	0
66	Metabolic Syndrome Is Associated With Aortic Stiffness in Untreated Essential Hypertension. Hypertension, 2005, 45, 1078-1082.	2.7	142
67	Impact of Treatment With Protease Inhibitors on Aortic Stiffness in Adult Patients With Human Immunodeficiency Virus Infection. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2381-2385.	2.4	92
68	Acute inflammatory state during influenza infection and endothelial function. Atherosclerosis, 2005, 178, 345-350.	0.8	27
69	Combined monogenic hypercholesterolemia and hypoalphalipoproteinemia caused by mutations in LDL-R and LCAT genes. Atherosclerosis, 2005, 182, 153-159.	0.8	18
70	Attenuation of inflammation with short-term dietary intervention is associated with a reduction of arterial stiffness in subjects with hypercholesterolaemia. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, 11, 497-502.	2.8	31
71	Attenuation of inflammation with short-term dietary intervention is associated with a reduction of arterial stiffness in subjects with hypercholesterolaemia. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, 11, 497-502.	2.8	51